A RANDOMIZED, SPLIT-FACE, PLACEBO-CONTROLLED TRIAL ON THE EFFECTIVENESS OF 0.1% ADENOSINE COMBINED WITH 5% MAGNESIUM ASCORBYL PHOSPHATE CREAM FOR PERIORBITAL WRINKLES

Abstract

This study examined the short-term effects and tolerability of a topical cream containing 0.1% adenosine combined with 5% magnesium ascorbyl phosphate (MAP) for the treatment of periorbital wrinkles compared with placebo. Fourteen healthy participants aged 30–50 years with visible periorbital wrinkles completed a randomized, double-blind, split-face, placebo-controlled trial. The active cream was applied nightly to one periorbital side and the placebo cream to the contralateral side. The primary endpoint was the between-side difference in change from baseline in Visioscan wrinkle score at week 12 and the secondary endpoint was the between-side difference in Cutometer R2 skin elasticity at week 12.The active-treatment side showed greater improvement than the placebo side in Visioscan wrinkle scores and Cutometer R2 measurements during the study period. At week 12, the mean between-side difference in change from baseline was 19.04 point for Visioscan wrinkle score and 0.0568 for Cutometer R2 (p = 0.009 and p < 0.001, respectively). Only one participant reported transient mild dryness, and no serious adverse events were observed. In conclusion, the fixed combination of 0.1% adenosine and 5% magnesium ascorbyl phosphate was associated with short-term improvements in objective skin measurements and was generally well tolerated in this small sample. These findings support further investigation of the formulation but do not establish long-term effectiveness or ingredient-specific effects.